argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
argenx SE presented long-term data for its FcRn blocker drug efgartigimod, showing sustained clinical improvements and favorable safety profiles in patients with myositis and Sjogren's disease. Data from ongoing extension studies ALKIVIA+ and RHO+ demonstrate maintained disease activity reduction and tolerability over 52 and 72 weeks respectively. …